Aquestive Therapeutics, Inc. (AQST) Stock Analysis & Investment Frameworks
Aquestive Therapeutics, Inc. (AQST) stock analysis on Invetso. Review Aquestive Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Aquestive Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Aquestive Therapeutics, Inc. Key Financial Metrics
- Market Cap: $508.32M
- Revenue: $44.55M
- ROE: 243.68%
- ROIC: -45.30%
- Dividend Yield: N/A
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Aquestive Therapeutics, Inc. Investment Frameworks
Invetso analyzes Aquestive Therapeutics, Inc. (AQST) across the following frameworks:
- Aquestive Therapeutics, Inc. 10Y Growth Potential
- Aquestive Therapeutics, Inc. Scenario Analysis
- Aquestive Therapeutics, Inc. Risks & Opportunities
- Aquestive Therapeutics, Inc. Economic Moat
- Aquestive Therapeutics, Inc. Business Model
- Aquestive Therapeutics, Inc. Management
- Aquestive Therapeutics, Inc. SWOT Analysis
- Aquestive Therapeutics, Inc. Porter's 5 Forces
- Aquestive Therapeutics, Inc. PESTLE Analysis
- Aquestive Therapeutics, Inc. ESG Analysis